Literature DB >> 583866

Fosfomycin: Laboratory studies.

H B Woodruff, J M Mata, S Hernández, S Mochales, A Rodríguez, E O Stapley, H Wallick, A K Miller, D Hendlin.   

Abstract

Fosfomycin, a nontoxic broad-spectrum antibiotic, different in structure from all previously described antibiotics, acts selectively by inhibiting cell wall formation. It was overlooked during many years of screening because of antagonism by culture medium ingredients and frequent occurrence of resistant mutants. It is effective in many because the neutralizing substances are not present and resistant mutants of most species are avirulent. Fosfomycin has favorable pharmacologic characteristics. It is not cross resistant, does not show antagonism, and has been used successfully in combinations. An insoluble calcium salt is used in oral formulation and a sodium salt for parenteral administration. Overall success rates of 86% were reported with 1,000 patients in Spain and 79% in Japan.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 583866     DOI: 10.1159/000222020

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  16 in total

Review 1.  Fosfomycin: an old, new friend?

Authors:  M Popovic; D Steinort; S Pillai; C Joukhadar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-11-14       Impact factor: 3.267

Review 2.  Challenges of antibacterial discovery.

Authors:  Lynn L Silver
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

3.  Single- and combination-antibiotic therapy for experimental endocarditis caused by methicillin-resistant Staphylococcus aureus.

Authors:  A Rodríguez; M V Vicente; T Olay
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

4.  Comparison of fosfomycin and vancomycin therapy for experimental endocarditis due to methicillin-resistant Staphylococcus epidermidis.

Authors:  A Rodríguez; M V Vicente; T Olay
Journal:  Eur J Clin Microbiol       Date:  1985-12       Impact factor: 3.267

5.  [Fosfomycin concentrations in serum and bile (author's transl)].

Authors:  O Müller; U Rückert; W Walter; R Haag; W Sauer
Journal:  Infection       Date:  1982-01       Impact factor: 3.553

6.  In vitro activity of fludalanine combined with pentizidone compared with those of other agents.

Authors:  R Wise; J M Andrews
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

7.  In vitro evaluation of combined usage of fosfomycin and 5-fluorouracil for selective isolation of Leptospira species.

Authors:  S Oie; A Koshiro; H Konishi; Z Yoshii
Journal:  J Clin Microbiol       Date:  1986-06       Impact factor: 5.948

8.  In vitro investigations with fosfomycin on Mueller-Hinton agar with and without glucose-6-phosphate.

Authors:  H Grimm
Journal:  Infection       Date:  1979       Impact factor: 3.553

9.  [In vitro effect of fosfomycin against Pseudomonas aeruginosa compared to carbenicillin, gentamycin and polymyxin B].

Authors:  R Ansorg
Journal:  Infection       Date:  1978       Impact factor: 3.553

10.  Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis.

Authors:  David L MacLeod; Lynn M Barker; Jennifer L Sutherland; Suzanne C Moss; Jesse L Gurgel; Thomas F Kenney; Jane L Burns; William R Baker
Journal:  J Antimicrob Chemother       Date:  2009-08-13       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.